Aptose to Report Third Quarter 2022 Financial Results and&#x

SAN DIEGO and TORONTO, Oct. 18, 2022 -- Aptose Biosciences Inc. , a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic... | October 18, 2022

Related Keywords

Toronto , Ontario , Canada , Aptose Biosciences , Susan Pietropaolo , Lifesci Advisors , Aptose Biosciences Inc , Nasdaq , Globenewswire Inc , Webcast Only , Participant Registration , Investor Relations , Sci Advisors , Managing Director , Aptose Biosciences Inc Stock Exchange , News , Information , Press Release , Han , Iego , End , 022 , Aptose , Iosciences , Stage , Precision , Ncology , Company , Developing , Ighly , Differentiated , Mural , Inase , Inhibitors , O , Reat Aps Ca03835t2002 ,